[{"id":"065bb339-f105-4508-b885-dd7c099feef1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02944357","created_at":"2021-01-18T14:27:27.728Z","updated_at":"2024-07-02T16:37:16.298Z","phase":"","brief_title":"Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery","source_id_and_acronym":"NCT02944357","lead_sponsor":"Mayo Clinic","biomarkers":" CD8 • PD-1","pipe":" | ","alterations":" PD-1 elevation","tags":["CD8 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • rocapuldencel-T (CMN-001)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 09/05/2017","primary_completion_date":" 09/05/2017","study_txt":" Completion: 09/05/2017","study_completion_date":" 09/05/2017","last_update_posted":"2017-11-17"}]